Optellum AI Shown to be Highly Cost-Effective in First US Lifetime Payer Study of Lung Nodule Risk Stratification
Led by researchers at the Vanderbilt University Medical Center, a new study reports that Optellum’s FDA-cleared Lung Cancer Prediction (LCP) AI assisted risk stratification for indeterminate lung nodules is cost-effective from a US payer perspective. Optellum’s LCP AI supports more consistent long nodule management and helps enable earlier diagnosis of lung cancer
March 24, 2026